

Edgar Filing: SPIRE CORP - Form 10QSB

SPIRE CORP
Form 10QSB
August 15, 2005

=====

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-QSB

- Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2005; or
- Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from _____ to _____

Commission file number: 0-12742

SPIRE CORPORATION

(Name of small business issuer as specified in its charter)

MASSACHUSETTS

04-2 57335

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification Number)

ONE PATRIOTS PARK
BEDFORD, MASSACHUSETTS 01730-2396

(Address of principal executive offices)

781-275-6000

(Issuer's telephone number)

Securities registered under Section 12(g) of the Act:
COMMON STOCK, \$0.01 PAR VALUE; REGISTERED ON THE NASDAQ STOCK MARKET

(Title of class)

Check whether the issuer: (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act). Yes No

State the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date. There were 6,864,366 outstanding shares of the issuer's only class of common equity, Common Stock,

Edgar Filing: SPIRE CORP - Form 10QSB

\$0.01 par value, on August 8, 2005.

=====

TABLE OF CONTENTS

| | Page |
|---|------|
| | ---- |
| PART I. FINANCIAL INFORMATION | |
| Item 1. Financial Statements | |
| Unaudited Condensed Consolidated Balance Sheet as of June 30, 2005. | 1 |
| Unaudited Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2005 and 2004..... | 2 |
| Unaudited Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2005 and 2004..... | 3 |
| Notes to Unaudited Condensed Consolidated Financial Statements..... | 4 |
| Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations..... | 12 |
| Item 3. Controls and Procedures..... | 22 |
| PART II. OTHER INFORMATION | |
| Item 1. Legal Proceedings..... | 23 |
| Item 2. Unregistered Sales of Equity Securities and Use of Proceeds..... | 24 |
| Item 3. Defaults Upon Senior Securities..... | 24 |
| Item 4. Submission of Matters to a Vote of Security Holders..... | 24 |
| Item 5. Other Information..... | 24 |
| Item 6. Exhibits..... | 24 |

PART I FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

SPIRE CORPORATION AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEET (UNAUDITED)

| | JUNE 30, 2005 |
|---------------------------|------------------|
| | ----- |
| ASSETS | |
| Current assets | |
| Cash and cash equivalents | \$7,576,064 |
| Restricted cash | 989,463 |

Edgar Filing: SPIRE CORP - Form 10QSB

| | |
|--|--------------|
| | ----- |
| | 8,565,527 |
| Accounts receivable - trade, net | 3,452,945 |
| Inventories, net | 2,401,547 |
| Prepaid expenses and other current assets | 582,334 |
| | ----- |
| Total current assets | 15,002,353 |
| Net property and equipment | 5,706,048 |
| Intangible and other assets (less accumulated amortization of \$653,361) | 694,752 |
| Available-for-sale investments at quoted market value | 886,420 |
| Restricted cash - long-term | 199,821 |
| Deposit - related party | 191,250 |
| | ----- |
| Total assets | \$22,680,644 |
| | ===== |
| LIABILITIES AND STOCKHOLDERS' EQUITY | |
| Current liabilities | |
| Current portion of capital lease obligation | \$ 415,947 |
| Current portion of capital lease obligation - related party | 620,999 |
| Accounts payable | 2,242,510 |
| Accrued liabilities | 1,894,762 |
| Accrued lease obligation - related party | 217,411 |
| Advances on contracts in progress | 2,020,093 |
| | ----- |
| Total current liabilities | 7,411,722 |
| | ----- |
| Long-term portion of capital lease obligation | 235,082 |
| Long-term portion of capital lease obligation - related party | 1,924,696 |
| Deferred compensation | 886,420 |
| Unearned purchase discount | 1,216,183 |
| | ----- |
| Total long-term liabilities | 4,262,381 |
| | ----- |
| Total liabilities | 11,674,103 |
| | ----- |
| Commitments and Contingencies: | |
| Stockholders' equity | |
| Common stock, \$0.01 par value; 20,000,000 shares authorized; 6,856,616 shares issued and outstanding | 68,566 |
| Additional paid-in capital | 9,468,506 |
| Retained earnings | 1,468,320 |
| Accumulated other comprehensive income | 1,149 |
| | ----- |
| Total stockholders' equity | 11,006,541 |
| | ----- |
| Total liabilities and stockholders' equity | \$22,680,644 |
| | ===== |

See accompanying notes to condensed consolidated financial statements.

Edgar Filing: SPIRE CORP - Form 10QSB

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

| | THREE MONTHS ENDED JUNE 30, | | SIX MONTHS ENDED |
|--|-----------------------------|--------------|------------------|
| | 2005 | 2004 | 2005 |
| Net sales and revenues | | | |
| Contract research, service and license revenues | \$ 2,809,657 | \$ 2,748,874 | \$ 5,541,671 |
| Sales of goods | 4,537,458 | 1,508,991 | 5,984,959 |
| Total net sales and revenues | 7,347,115 | 4,257,865 | 11,526,630 |
| Costs and expenses | | | |
| Cost of contract research, service and licenses | 2,157,660 | 2,113,125 | 4,275,465 |
| Cost of goods sold | 4,291,820 | 1,388,027 | 5,710,580 |
| Selling, general and administrative expenses | 2,057,026 | 2,030,134 | 3,886,605 |
| Internal research and development expenses | 340,873 | 377,340 | 658,069 |
| Total costs and expenses | 8,847,379 | 5,908,626 | 14,530,719 |
| Gain on sale of licenses | 6,319,600 | 3,000,000 | 6,319,600 |
| Earnings from operations | 4,819,336 | 1,349,239 | 3,315,511 |
| Other expense, net | (121,184) | (70,529) | (197,801) |
| Earnings (loss) before income taxes | 4,698,152 | 1,278,710 | 3,117,710 |
| Income tax expense | -- | -- | -- |
| Net earnings (loss) | \$ 4,698,152 | \$ 1,278,710 | \$ 3,117,710 |
| Earnings (loss) per share of common stock - basic | \$ 0.69 | \$ 0.19 | \$ 0.45 |
| Earnings (loss) per share of common stock - diluted | \$ 0.67 | \$ 0.18 | \$ 0.44 |
| Weighted average number of common and common equivalent shares outstanding - basic | 6,856,616 | 6,789,206 | 6,855,783 |
| Weighted average number of common and common equivalent shares outstanding - diluted | 7,042,492 | 7,062,623 | 7,045,315 |

Edgar Filing: SPIRE CORP - Form 10QSB

=====

See accompanying notes to condensed consolidated financial statements.

2

SPIRE CORPORATION AND SUBSIDIARIES
 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
 (UNAUDITED)

| | SIX MONTHS ENDED JUNE 30 | |
|--|--------------------------|--------------|
| | 2005 | 2004 |
| | ----- | ----- |
| Cash flows from operating activities: | | |
| Net income (loss) | \$ 3,117,710 | \$ (99,000) |
| Adjustments to reconcile net income (loss) to net cash used in operating activities: | | |
| Depreciation and amortization | 1,245,007 | 1,244,000 |
| Gain on sale of licenses | (6,319,600) | (3,000,000) |
| Deferred compensation | (23,407) | - |
| Unearned purchase discount | (54,128) | (73,000) |
| Changes in assets and liabilities: | | |
| Restricted cash | (379,574) | (7,000) |
| Accounts receivable, net | 774,933 | 95,000 |
| Inventories | 322,891 | (557,000) |
| Prepaid expenses and other current assets | (27,920) | 335,000 |
| Accounts payable, accrued liabilities and other liabilities | 445,982 | (316,000) |
| Deposit - related party | (22,500) | (168,000) |
| Advances on contracts in progress | (578,653) | (378,000) |
| | ----- | ----- |
| Net cash used in operating activities | (1,499,259) | (2,925,000) |
| | ----- | ----- |
| Cash flows from investing activities: | | |
| Proceeds from sale of licenses | 6,319,600 | 3,000,000 |
| Additions to property and equipment | (166,719) | (197,000) |
| Restricted cash - long term | 17,979 | - |
| Increase in intangible and other assets | (5,117) | (305,000) |
| | ----- | ----- |
| Net cash provided by investing activities | 6,165,743 | 2,497,000 |
| | ----- | ----- |
| Cash flows from financing activities: | | |
| Principal payment on capital lease obligations | (197,336) | (184,000) |
| Principal payment on capital lease obligations - related parties | (250,652) | (171,000) |
| Exercise of stock options | 20,701 | 132,000 |
| | ----- | ----- |
| Net cash used in financing activities | (427,287) | (223,000) |
| | ----- | ----- |
| Net increase (decrease) in cash and cash equivalents | 4,239,197 | (650,000) |
| Cash and cash equivalents, beginning of period | 3,336,867 | 5,999,000 |
| | ----- | ----- |
| Cash and cash equivalents, end of period | \$ 7,576,064 | \$ 5,348,000 |
| | ===== | ===== |
| Cash paid during the period for: | | |

Edgar Filing: SPIRE CORP - Form 10QSB

| | | |
|--------------------------|------------|---------|
| Interest | \$ 11,235 | \$ 31, |
| | ===== | ===== |
| Interest - related party | \$ 103,060 | \$ 109, |
| | ===== | ===== |
| Income taxes | \$ 110,064 | \$ - |
| | ===== | ===== |

See accompanying notes to condensed consolidated financial statements.

3

SPIRE CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

JUNE 30, 2005

1. DESCRIPTION OF THE BUSINESS

The Company develops, manufactures and markets highly-engineered products and services in four principal business areas: biomedical, solar equipment, solar systems and optoelectronics bringing to bear expertise in materials technologies across all four business areas.

In the biomedical area, the Company provides value-added surface treatments to manufacturers of orthopedic and other medical devices that enhance the durability, antimicrobial characteristics or other material characteristics of their products; develops and markets hemodialysis catheters and related devices for the treatment of chronic kidney disease and performs sponsored research programs into practical applications of advanced biomedical and biophotonic technologies.

In the solar equipment area, the Company develops, manufactures and markets specialized equipment for the production of terrestrial photovoltaic modules from solar cells. The Company's equipment has been installed in more than 150 factories in 43 countries.

In the solar systems area, the Company provides custom and building integrated photovoltaic modules, stand alone emergency power backup and electric power grid-connected distributed power generation systems employing photovoltaic technology developed by the Company.

In the optoelectronics area, the Company provides compound semiconductor foundry services on a merchant basis to customers involved in biomedical/biophotonic instruments, telecommunications and defense applications. Services include compound semiconductor wafer growth, other thin film processes and related device processing and fabrication services. The Company also provides materials testing services and performs services in support of sponsored research into practical applications of optoelectronic technologies.

2. INTERIM FINANCIAL STATEMENTS

In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to fairly present the Company's financial position as of June 30, 2005 and the results of its operations and cash flows for the three and six months ended June 30, 2005 and 2004. The results of operations for the three and six months ended June 30, 2005 are not necessarily indicative of the results to be expected for the fiscal year ending December 31, 2005.

Edgar Filing: SPIRE CORP - Form 10QSB

The accounting policies followed by the Company are set forth in Footnote 2 to the Company's consolidated financial statements in its annual report on Form 10-KSB for the year ended December 31, 2004.

Certain prior period accounts have been reclassified to conform with current presentation.

3. ACCOUNTS RECEIVABLE/ADVANCES ON CONTRACTS IN PROGRESS

Net accounts receivable, trade consists of the following:

| | June 30, 2005 ----- |
|---|---------------------------|
| Amounts billed | \$3,333,925 |
| Retainage | 34,869 |
| Accrued revenue | 271,723 ----- |
| | 3,640,517 |
| Less: Allowance for sales returns and doubtful accounts | (187,572) ----- |
| Net accounts receivable | \$3,452,945 ===== |
| Advances on contracts in progress | \$2,020,093 ===== |

4

SPIRE CORPORATION AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED) (UNAUDITED)

JUNE 30, 2005

Accrued revenue represents revenues recognized on contracts for which billings have not been presented to customers as of the balance sheet date. These amounts are billed and generally collected within one year.

Retainage represents revenues on certain United States government sponsored research and development contracts. These amounts, which usually represent 15% of the Company's research fee on each applicable contract, are not collectible until a final cost review has been performed by government auditors. Included in retainage are amounts expected to be collected after one year, which totaled \$35,000 at June 30, 2005. All other accounts receivable are expected to be collected within one year.

All contracts with United States government agencies have been audited by the government through December 2002. The Company has not incurred significant losses or adjustments as a result of government audits.

The Company maintains allowances for doubtful accounts for estimated losses resulting from the inability of its customers to pay amounts due. Bad debts are written off against the allowance when identified. In addition, the Company maintains an allowance for potential future product returns and rebates related to current period revenues. The Company analyzes the rate of historical returns when evaluating the adequacy of the allowance for sales returns and allowances. Returns and rebates are charged against the allowance when incurred.

Advances on contracts in progress represent contracts for which billings have been presented to the customer but revenue has not been recognized.

Edgar Filing: SPIRE CORP - Form 10QSB

4. INVENTORIES

Inventories consist of the following:

| | June 30, 2005 |
|-----------------|------------------|
| | ----- |
| Raw materials | \$1,435,527 |
| Work in process | 728,167 |
| Finished goods | 237,853 |
| | ----- |
| | \$2,401,547 |
| | ===== |

5. EARNINGS (LOSS) PER SHARE

The following table provides a reconciliation of the denominators of the Company's reported basic and diluted earnings (loss) per share computations for the periods ended:

| | Three Months Ended June 30, | | Six Months Ended June 30, | |
|--|--------------------------------|-----------|------------------------------|-----------|
| | 2005 | 2004 | 2005 | 2004 |
| | ----- | ----- | ----- | ----- |
| Weighted average number of common and common equivalent shares outstanding - basic | 6,856,616 | 6,789,206 | 6,855,783 | 6,777,368 |
| Add: Net additional common shares upon assumed exercise of common stock options | 185,876 | 273,417 | 189,532 | -- |
| | ----- | ----- | ----- | ----- |
| Adjusted weighted average common and common equivalent shares outstanding - diluted | 7,042,492 | 7,062,623 | 7,045,315 | 6,777,368 |
| | ===== | ===== | ===== | ===== |

For the three and six months ended June 30, 2005, 84,568 and 84,535 shares, respectively, and for the three and six months ended June 30, 2004, 80,069 and 67,815 shares, respectively, of common stock issuable relative to stock options

6

SPIRE CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
(UNAUDITED)

JUNE 30, 2005

had exercise prices per share that exceeded the average market price of the Company's common stock and were excluded from the calculation of diluted shares since their inclusion would be anti-dilutive. For the six months ended June 30, 2004, 263,234 shares of common stock issuable relative to stock options were excluded from the calculation of dilutive shares since the inclusion of such shares would be anti-dilutive due to the Company's net loss position in the period.

6. OPERATING SEGMENTS AND RELATED INFORMATION

Edgar Filing: SPIRE CORP - Form 10QSB

The following table presents certain operating division information in accordance with the provisions of SFAS No. 131, "Disclosure about Segments of an Enterprise and Related Information."

| | Solar Equipment | Solar Systems | Biomedical | Optoelectr |
|--|--------------------|------------------|-------------|------------|
| For the three months ended June 30, 2005 | | | | |
| Net sales and revenues | \$2,437,322 | \$1,522,541 | \$2,785,042 | \$ 602, |
| Earnings (loss) from operations | 2,643,812 | (75,764) | 2,891,836 | (640, |
| For the three months ended June 30, 2004 | | | | |
| Net sales and revenues | \$ 813,024 | \$ 510,550 | \$2,323,307 | \$ 610, |
| Earnings (loss) from operations | (506,278) | (152,209) | 2,592,041 | (584, |
| For the six months ended June 30, 2005 | | | | |
| Net sales and revenues | \$3,379,315 | \$1,575,991 | \$5,278,138 | \$1,293, |
| Earnings (loss) from operations | 2,253,706 | (471,695) | 2,754,426 | (1,220, |
| For the six months ended June 30, 2004 | | | | |
| Net sales and revenues | \$1,974,691 | \$1,787,871 | \$4,180,699 | \$1,344, |
| Earnings (loss) from operations | (669,203) | (62,059) | 1,768,006 | (996, |

Earnings from operations for the solar equipment and biomedical segments include gains on the sale of licenses of \$3,319,600 and \$3,000,000, respectively, for the three and six months ended June 30, 2005. These gains are more fully described in Footnote 12.

The following table shows net sales and revenues by geographic area (based on customer location):

| | Three Months Ended June 30, | | | | Six Months Ended J | | | |
|---------------|-----------------------------|------|--------------|------|--------------------|------|--------------|------|
| | 2005 | % | 2004 | % | 2005 | % | 2004 | % |
| Foreign | \$ 2,650,000 | 36% | \$ 910,000 | 21% | \$ 3,277,000 | 29% | \$ 1,465,000 | 16% |
| United States | 4,697,000 | 64% | 3,348,000 | 79% | 8,250,000 | 71% | 8,250,000 | 71% |
| | \$ 7,347,000 | 100% | \$ 4,258,000 | 100% | \$11,527,000 | 100% | \$11,527,000 | 100% |

Revenues from contracts with United States government agencies for the three months ended June 30, 2005 and 2004 were \$788,000 and \$819,000, or 11% and 19% of consolidated net sales and revenues, respectively.

Revenues from contracts with United States government agencies for the six months ended June 30, 2005 and 2004 were \$1,681,000 and \$1,465,000, or 15% and 16% of consolidated net sales and revenues, respectively.

Four customers accounted for approximately 51% for the three months ended June 30, 2005 and one customer accounted for approximately 15% of the Company's gross sales during the three months ended June 30, 2004. One customer accounted for approximately 15% for the six months ended June 30, 2005 and two customers accounted for approximately

Edgar Filing: SPIRE CORP - Form 10QSB

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
(UNAUDITED)

JUNE 30, 2005

24% of the Company's gross sales during the six months ended June 30, 2004. One customer represented approximately 11% of trade account receivables at June 30, 2005.

7. INTANGIBLE AND OTHER ASSETS

Patents amounted to \$511,720, net of accumulated amortization of \$584,254, at June 30, 2005. Licenses amounted to \$155,893, net of accumulated amortization of \$69,107, at June 30, 2005. Patent cost is primarily composed of cost associated with securing and registering patents that the Company has been awarded or that have been submitted to, and the Company believes will be approved by, the government. These costs are capitalized and amortized over their useful lives or terms, ordinarily five years, using the straight-line method. There are no expected residual values related to these patents. For disclosure purposes, the table below includes future amortization expense for patents owned by the Company as well as \$420,318 of estimated amortization expense related to patents that remain pending. Estimated amortization expense for the periods ending December 31, is as follows:

| Year | Amortization Expense |
|-----------------|-------------------------|
| ---- | ----- |
| 2005 | \$83,496 |
| 2006 | 164,518 |
| 2007 | 157,366 |
| 2008 | 130,319 |
| 2009 and beyond | 131,914 |
| | ----- |
| | \$667,613 |
| | ===== |

Also included in other assets are \$27,139 of refundable deposits made by the Company.

8. AVAILABLE-FOR-SALE INVESTMENTS

Available-for-sale securities consist of the following:

| | |
|-----------------------------|------------------|
| | June 30, 2005 |
| | ----- |
| Equity investments | \$559,538 |
| Government bonds | 168,701 |
| Cash and money market funds | 158,181 |
| | ----- |
| | \$886,420 |
| | ===== |

These investments have been classified as available-for-sale and are reported at fair value, with unrealized gains and losses included in accumulated other comprehensive loss, net of related tax effect. As of June 30, 2005, the unrealized gain on these marketable securities was approximately \$2,000.

9. NOTES PAYABLE AND CREDIT ARRANGEMENTS

The Company has a \$2,000,000 Loan Agreement (the "Agreement") with Citizens

Edgar Filing: SPIRE CORP - Form 10QSB

Bank of Massachusetts (the "Bank"). The Agreement provides Standby Letter of Credit guarantees for certain foreign and domestic customers, which are 100% secured with cash. At June 30, 2005, the Company had approximately \$1,189,000 of restricted cash associated with outstanding Letters of Credit. Standby Letters of Credit under this Agreement bear interest at 1%. The Agreement also provides the Company with the ability to convert to a \$2,000,000 revolving line of credit, based upon eligible accounts receivable and certain conversion covenants. Loans under this revolving line of credit bear interest at the Bank's prime rate, as determined, plus 1/2% (6.75% at June 30, 2005.) At June 30, 2005, the Company had not exercised its conversion option and no amounts were outstanding under the revolving line of credit. A commitment fee of .25% is charged on the unused portion of the borrowing base. On June 29, 2005, the Company entered into a Second Amendment to extend the expiration date of the Agreement to June 27, 2006. The Agreement contains covenants including certain financial reporting

7

SPIRE CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
(UNAUDITED)

JUNE 30, 2005

requirements. At June 30, 2005, the Company was in compliance with its financial reporting requirements and cash balance covenants.

10. STOCK-BASED COMPENSATION

The Company has adopted the disclosure provisions of Statement of Financial Accounting Standards No. 148, "Accounting for Stock-Based Compensation - Transition and Disclosure" ("SFAS 148") which is an amendment of SFAS No. 123 "Accounting for Stock-Based Compensation" ("SFAS 123"), and continues to apply Accounting Principles Board Opinion No. 25 and related interpretations in accounting for its stock plans. If the Company had elected to recognize compensation cost for all of the plans based upon the fair value at the grant dates for awards under those plans, consistent with the method prescribed by SFAS 123, net earnings (loss) and earnings (loss) per share would have been changed to the pro forma amounts indicated below.

| | Three Months Ended June 30, | | Six Months Ended June 30, | |
|---|--------------------------------|-------------|------------------------------|--------------|
| | 2005 | 2004 | 2005 | 2004 |
| Net earnings (loss), as reported | \$4,698,152 | \$1,278,710 | \$3,117,710 | \$ (99,000) |
| Deduct: Total stock-based employee compensation expense determined under fair value based method for all awards, net of related tax effects | (76,882) | (80,424) | (158,658) | (158,658) |
| Pro forma net earnings (loss) | \$4,621,270 | \$1,198,286 | \$2,959,052 | \$ (258,658) |
| Earnings (loss) per share: | | | | |
| Basic - as reported | \$ 0.69 | \$ 0.19 | \$ 0.45 | \$ (0.40) |
| Basic - pro forma | \$ 0.67 | \$ 0.18 | \$ 0.43 | \$ (0.40) |

Edgar Filing: SPIRE CORP - Form 10QSB

| | | | | |
|-----------------------|---------|---------|---------|-------|
| Diluted - as reported | \$ 0.67 | \$ 0.18 | \$ 0.44 | \$ (|
| | ===== | ===== | ===== | ===== |
| Diluted - pro forma | \$ 0.66 | \$ 0.17 | \$ 0.42 | \$ (|
| | ===== | ===== | ===== | ===== |

The per-share weighted-average fair value of stock options granted during the quarters ended June 30, 2005 and 2004 was \$2.91 and \$4.73, respectively, on the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions:

| Year | Expected Dividend Yield | Risk-Free Interest Rate | Expected Option Life | Expected Volatility Factor |
|------|-------------------------|-------------------------|----------------------|----------------------------|
| ---- | ----- | ----- | ----- | ----- |
| 2005 | -- | 3.94% | 5 years | 76.6% |
| 2004 | -- | 3.83% | 5 years | 78.2% |

For the quarter ended June 30, 2005, 69,250 stock options were granted.

In December 2004, the Financial Accounting Standards Board issued SFAS No. 123R, SHARE-BASED PAYMENT. SFAS No. 123R requires companies to expense the value of employee stock option and similar awards. SFAS No. 123R is effective as of the beginning of the first interim or annual reporting period that begins after December 15, 2005. As of the effective date, the Company will be required to expense all awards granted, modified, cancelled or repurchased as well as the portion of prior awards for which the requisite service has not been rendered, based on the grant-date fair value of those awards as calculated for pro forma disclosures under SFAS No. 123. The adoption of SFAS No. 123R's fair value method will have an impact on the Company's results of operations. The Company is currently in the process of determining the effects on its financial position, results of operations and cash flows that will result from the adoption of SFAS No. 123R.

8

SPIRE CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
(UNAUDITED)

JUNE 30, 2005

11. COMPREHENSIVE INCOME (LOSS)

Comprehensive income (loss) includes certain changes in equity that are excluded from net earnings (loss) and consists of the following:

| | For the Three Months Ended June 30, | | For the Six Months Ended June 30, | |
|---|-------------------------------------|-------------|-----------------------------------|-------------|
| | 2005 | 2004 | 2005 | 2004 |
| | ----- | ----- | ----- | ----- |
| Net earnings (loss) | \$4,698,152 | \$1,278,710 | \$3,117,710 | \$ (99,345) |
| Other comprehensive loss: | | | | |
| Net unrealized loss on available for sale marketable securities, net of tax | (6,295) | -- | (23,407) | -- |
| | ----- | ----- | ----- | ----- |
| Total comprehensive income (loss) | \$4,691,857 | \$1,278,710 | \$3,094,303 | \$ (99,345) |
| | ===== | ===== | ===== | ===== |

Edgar Filing: SPIRE CORP - Form 10QSB

12. SALE OF LICENSES

In October 2002, the Company sold an exclusive patent license for a hemodialysis split-tip catheter to Bard Access Systems, Inc. ("Bard"), a wholly owned subsidiary of C. R. Bard, Inc., in exchange for \$5,000,000 upon the execution of the agreement, with another \$5,000,000 due upon the earlier to occur of: (a) the date of the first commercial sale of a licensed product by Bard; or (b) no more than 18 months after signing. The agreement further provided for two additional contingent cash payments of \$3,000,000 each upon the completion of certain milestones by Bard in 2004 and 2005. Bard has the right to cancel the agreement at any time subsequent to the second payment. During the year ended December 31, 2002, the Company recorded the initial payment under the agreement, resulting in a gain of \$4,464,929, net of direct costs. Due to the potential length of time between the first and second payments and the cancellation provisions within the agreement, the Company did not record the potential remaining payments at that time. During June 2003, in accordance with the agreement, the Company received notification from Bard of the first commercial sale, collected the \$5,000,000 payment due and recorded a gain of \$4,989,150, net of direct costs. In June 2004, the Company received the first contingent milestone payment and recorded a gain of \$3,000,000. In June 2005, the Company received the second and final contingent milestone payment and recorded a gain of \$3,000,000. There were no direct costs associated with these payments. These gains have been recorded in the accompanying unaudited condensed consolidated statements of operations for three and six months ended June 30, 2005 and 2004, respectively.

In conjunction with the sale, the Company received a sublicense, which permits the Company to continue to manufacture and market hemodialysis catheters for the treatment of chronic kidney disease. In addition, the Company granted Bard a right of first refusal should the Company seek to sell the catheter business.

On May 26, 2005, the Company entered into a global consortium agreement (the "Agreement") with Nisshinbo Industries, Inc. (Nisshinbo) for the development, manufacturing, and sales of solar photovoltaic module manufacturing equipment. Under the terms of the Agreement, Nisshinbo purchased a license to manufacture and sell the Company's module manufacturing equipment for an upfront fee plus additional royalties based on ongoing equipment sales over a ten-year period. In addition, the Company and Nisshinbo agreed, but are not obligated, to pursue joint research and development, product improvement activities and sales and marketing efforts. On June 27, 2005, the Company received JPY 400,000,000 from the sale of this permanent license. The Company has determined the fair value of the license and royalty based on an appraisal. As a result, a \$3,319,600 gain has been recognized as a gain on sale of license in the accompanying unaudited condensed consolidated statements of operations for the three and six months ended June 30, 2005. In addition, approximately \$13,000 of royalty income was recognized during the quarter.

As of June 30, 2005, JPY 400,000,000 was held in a Japanese yen account. This yen account has been reflected in cash and cash equivalents in the accompanying unaudited condensed consolidated balance sheet utilizing the closing yen/dollar exchange rate as of June 30, 2005. As a result, a \$62,845 currency transaction loss was incurred and reflected in Other expense, net in the accompanying unaudited condensed consolidated statement of operations for the three and six months ended June 30, 2005. On July 1, the Company entered into a 30-day Forward Plus Contract with its Bank for the conversion of the majority of its Yen account into United States dollars at a predetermined exchange rate range. This contract effectively capped the Company's exchange rate at 113.25 while allowing the Company to benefit from decreases in the yen / dollar exchange rate to a 109.25 limit. If the rate dropped below this limit at the expiration date of the contract,

Edgar Filing: SPIRE CORP - Form 10QSB

9

SPIRE CORPORATION AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED) (UNAUDITED)

JUNE 30, 2005

the Company would have to convert the yen at the 113.25 rate. On August 3, 2005, the Company converted JPY 350,000,000 into \$3,139,295 and the contract expired.

The Company believes that the sale of these licenses does not reflect the day-to-day operations of the Company. Therefore, the net proceeds received have been classified under investing activities in the unaudited condensed consolidated statements of cash flows for the six months ended June 30, 2005 and June 30, 2004, respectively.

13. NASDAQ LISTING

On April 6, 2005, the Company received a letter from the Nasdaq Listing Qualifications Panel (the "Nasdaq Panel") indicating that the Company is no longer in compliance with the \$10,000,000 minimum stockholders' equity requirement for continued listing set forth in Nasdaq Marketplace Rule 4450(a)(3) (the "Rule"). The Nasdaq Panel requested that the Company provide, by April 13, 2005, the Company's plan to achieve and sustain compliance with this requirement. On April 13, 2005, the Company presented such plan to the Nasdaq Panel.

On April 25, 2005, the Company received a letter from the Nasdaq Panel informing the Company that the Nasdaq Panel was remanding this case to the Nasdaq Staff. The Nasdaq Panel indicated that it believes that the Nasdaq Staff is the appropriate body to review and evaluate the Company's plan of compliance, following its normal procedures and processes.

On April 27, 2005, the Nasdaq Staff issued a Determination letter reiterating the Nasdaq Panel's April 6, 2005 finding that the Company is no longer in compliance with the Rule, and that the Nasdaq Staff will review the Company's eligibility for continued National Market listing. The Nasdaq Staff requested that the Company provide a plan to achieve and sustain compliance with Nasdaq listing standards. On May 12, 2005, the Company submitted such a plan to the Nasdaq Staff.

On May 24, 2005, the Nasdaq Staff requested additional information from the Company regarding certain projected nonrecurring license sales that were expected to occur during the second quarter of 2005. On June 3, 2005, the Company submitted a revised plan to achieve compliance with the Rule incorporating the subject license sales. On June 6, 2005, the Company received a letter from the Nasdaq Staff stating that the Company provided a definitive plan evidencing its ability to achieve and sustain compliance with the Rule, and as such, granted the Company an extension of time to achieve compliance. The terms of the extension required the Company to file a Form 8-K providing an update on the Company's listing status. The Company made such filing on August 5, 2005. The license sales completed during the three months ended June 30, 2005 are described in Footnote 12 above. As a result of these transactions, the Company believes that it has regained compliance with the Rule as of June 30, 2005.

Nasdaq will continue to monitor the Company's ongoing compliance with the Rule. If the Company were to receive a written notification of delisting from Nasdaq, it could appeal the decision to a Nasdaq Listing Qualifications Panel. If such an appeal were unsuccessful, the Company could apply to list the

Edgar Filing: SPIRE CORP - Form 10QSB

Company's common stock on the Nasdaq SmallCap Market. Although the Company believes it has regained compliance with the Rule as of June 30, 2005, in order to avoid future listing problems with respect to the Nasdaq National Market, the Company may still decide to apply to transfer the listing of its common stock to the Nasdaq SmallCap Market.

14. COMMITMENTS AND CONTINGENCIES

Agreement with BP Solarex

On October 8, 1999, the Company entered into an Agreement with BP Solarex ("BPS") in which BPS agreed to purchase certain production equipment built by the Company, for use in the Company's Chicago factory ("Spire Solar Chicago") and in return the Company agreed to purchase solar cells of a minimum of two megawatts per year over a five-year term for a fixed fee from BPS (the "Purchase Commitment"). BPS has the right to reclaim the equipment should the Company not meet its obligations in the Purchase Commitment. The proceeds from the sale of the production equipment purchased by BPS have been classified as an unearned purchase discount in the accompanying unaudited condensed consolidated balance sheet. The Company will amortize this discount as a reduction to cost of sales as it purchases solar cells from BPS. During the quarter ended September 30, 2003, the Company and BPS retroactively amended the agreement

10

SPIRE CORPORATION AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED) (UNAUDITED)

JUNE 30, 2005

to include all purchases of solar modules, solar systems, inverter systems and other system equipment purchased by the Company from BPS in the purchase commitment calculation. Amortization of the purchase discount amounted to \$54,128 for the six months ended June 30, 2005. The production equipment has been classified as a component of fixed assets in the accompanying unaudited condensed consolidated balance sheet. Depreciation amounted to \$136,256 for the six months ended June 30, 2005.

In addition, the agreement contains a put option for BPS to have the Company create a separate legal entity for Spire Solar Chicago and for BPS to convert the value of the equipment and additional costs, as defined, into equity of the new legal entity. The percentage ownership in the joint venture would be determined based on the cumulative investments by BPS and the Company.

The amended agreement also allows the Company to terminate the agreement on 30 days notice in consideration for a termination payment based on the aggregate amount of Spire purchases of BPS products and the fair market value of the production equipment purchased by BPS at the time of the termination election. The Company is currently exploring various options with regard to this agreement including a potential purchase of the production equipment. As of June 30, 2005 a definitive decision has not been made in this matter

Legal Matters

From time to time, the Company is subject to legal proceedings and claims arising from the conduct of its business operations. The Company does not expect the outcome of these proceedings, either individually or in the aggregate, to have a material adverse effect on its financial position, results of operations,

Edgar Filing: SPIRE CORP - Form 10QSB

or cash flows.

The Company has been named as a defendant in 58 cases filed from August 2001 to July 2003 in state courts in Texas by persons claiming damages from the use of allegedly defective mechanical heart valves coated by a process licensed by the Company to St. Jude Medical, Inc., the valve manufacturer, which has also been named as a defendant in the cases. In June 2003, a judge in a state court in Harris County, Texas agreed to grant the Company's motion for summary judgment based upon the principle of federal preemption with regard to 57 of those cases and to order that the cases against the Company be dismissed with prejudice. An order to this effect was signed in late July 2003. The remaining case is still pending, and due to aspects of its fact situation is not subject to the principle of federal preemption. From August 2003 to date, a total of seven new cases were filed against the Company in courts in Harris County. Activity with regard to these cases is likely to occur only after the disposition of the original 57 cases is finally settled. The plaintiffs whose cases were dismissed have filed appeals with the Texas appellate court. In June 2005, the Texas Court of Appeals upheld the summary judgment granted by the lower court. Attorneys for the Company anticipate that the plaintiffs may file a motion for rehearing, and an appeal with the Texas Supreme Court is also possible. Attorneys who represent the Company with respect to these cases in Texas do not believe at this time that the actions of a federal district court judge in Minnesota in denying St. Jude Medical's request for summary judgment will materially affect the Company's position in the Texas complaints.

During the second quarter of 2005 a suit was filed by Arrow International, Inc. against Spire Biomedical, Inc., a wholly owned subsidiary of the Company, alleging patent infringement by the Company. The complaint claims one of the Company's catheter products induces and contributes to infringement when medical professionals insert it. The Company has responded to the complaint denying all allegations and has filed certain counterclaims. The Company intends to vigorously defend this matter. In the opinion of management, an unfavorable outcome of this matter could have a material adverse effect on the Company's financial position as well as its results of operations and cash flows.

11

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

THIS MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS SECTION AND OTHER PARTS OF THIS REPORT CONTAIN FORWARD-LOOKING STATEMENTS THAT INVOLVE RISKS AND UNCERTAINTIES. THE COMPANY'S ACTUAL RESULTS AND THE TIMING OF CERTAIN EVENTS MAY DIFFER SIGNIFICANTLY FROM THE RESULTS AND TIMING DISCUSSED IN THE FORWARD-LOOKING STATEMENTS. FACTORS THAT COULD CAUSE OR CONTRIBUTE TO SUCH DIFFERENCES INCLUDE, BUT ARE NOT LIMITED TO, THOSE DISCUSSED OR REFERRED TO IN THIS REPORT AND IN ITEM 6 OF THE ANNUAL REPORT ON FORM 10-KSB FOR THE YEAR ENDED DECEMBER 31, 2004. MANAGEMENT'S DISCUSSION AND ANALYSIS INCLUDES THE FOLLOWING SECTIONS:

- o Overview;
- o Results of Operations;
- o Three and Six Months Ended June 30, 2005 Compared to Three and Six Months Ended June 30, 2004;
- o Liquidity and Capital Resources;
- o Recent Accounting Pronouncements;
- o Impact of Inflation and Changing Prices;
- o Foreign Currency Fluctuation;
- o Related Party Transactions;
- o Critical Accounting Policies; and
- o Contractual Obligations, Commercial Commitments and Off-Balance Sheet

Edgar Filing: SPIRE CORP - Form 10QSB

Arrangements.

Overview

The Company develops, manufactures and markets highly-engineered products and services in four principal business areas: biomedical, solar equipment, solar systems and optoelectronics bringing to bear expertise in materials technologies across all four business areas.

In the biomedical area, the Company provides value-added surface treatments to manufacturers of orthopedic and other medical devices that enhance the durability, antimicrobial characteristics or other material characteristics of their products; develops and markets hemodialysis catheters and related devices for the treatment of chronic kidney disease and performs sponsored research programs into practical applications of advanced biomedical and biophotonic technologies.

In the solar equipment area, the Company develops, manufactures and markets specialized equipment for the production of terrestrial photovoltaic modules from solar cells. The Company's equipment has been installed in more than 150 factories in 43 countries.

In the solar systems area, the Company provides custom and building integrated photovoltaic modules, stand alone emergency power backup and electric power grid-connected distributed power generation systems employing photovoltaic technology developed by the Company.

In the optoelectronics area, the Company provides compound semiconductor foundry services on a merchant basis to customers involved in biomedical/biophotonic instruments, telecommunications and defense applications. Services include compound semiconductor wafer growth, other thin film processes and related device processing and fabrication services. The Company also provides materials testing services and performs services in support of sponsored research into practical applications of optoelectronic technologies.

Operating results will depend upon product mix, as well as the timing of shipments of higher priced products from the Company's solar equipment line and delivery of solar systems. Export sales were 29% of net sales and revenues in 2005 and are expected to continue to constitute a significant portion of the Company's net sales and revenues.

12

Results of Operations

The following table sets forth certain items as a percentage of net sales and revenues for the periods presented:

| | Three Months Ended June 30, | | Six Months Ended June 30, | |
|--|--------------------------------|------|------------------------------|------|
| | 2005 | 2004 | 2005 | 2004 |
| Net sales and revenues | 100% | 100% | 100% | 100% |
| Cost of sales and revenues | (87) | (82) | (86) | (80) |
| Gross profit | 13 | 18 | 14 | 20 |
| Selling, general and administrative expenses | (48) | (34) | (44) | |

Edgar Filing: SPIRE CORP - Form 10QSB

| | | | | |
|-------------------------------------|------|------|------|------|
| Internal research and development | (9) | (6) | (8) | (28) |
| | | | | (5) |
| Gain on sale of licenses | 86 | 71 | 55 | 32 |
| | ---- | ---- | ---- | ---- |
| Earnings from operations | 66 | 32 | 29 | -- |
| Other expense, net | (2) | (2) | (2) | (1) |
| | ---- | ---- | ---- | ---- |
| Earnings (loss) before income taxes | 64 | 30 | 27 | (1) |
| Income tax expense | -- | -- | -- | -- |
| | ---- | ---- | ---- | ---- |
| Net earnings (loss) | 64% | 30% | 27% | (1%) |
| | ==== | ==== | ==== | ==== |

OVERALL

The Company's total net sales and revenues for the six months ended June 30, 2005 ("2005") increased 24% compared to the six months ended June 30, 2004 ("2004"). The increase was attributable to the solar business unit and the biomedical business unit. These increases were partially offset by a decrease within the optoelectronics business unit.

SOLAR BUSINESS UNIT

Sales in the Company's solar business unit increased 32% during 2005 as compared to 2004 primarily due to a 109% increase in solar equipment sales resulting from the timing of the delivery of equipment partially offset by a 12% decrease in solar systems sales and an 18% decrease in revenue from government funded research and development activities associated with the cost sharing agreement with the Department of Energy National Renewable Energy Laboratory ("NREL").

BIOMEDICAL BUSINESS UNIT

Revenues of the Company's biomedical business unit increased 26% during 2005 as compared to 2004 as a result of a 95% increase in revenue from Spire's line of hemodialysis catheters and a 32% increase in revenue from Spire's government-funded research and development activities.

OPTOELECTRONICS BUSINESS UNIT

Sales in the Company's optoelectronics business unit decreased 4% during 2005.

Three and Six Months Ended June 30, 2005 Compared to Three and Six Months Ended

June 30, 2004

NET SALES AND REVENUES

The following table categorizes the Company's net sales and revenues for the periods presented:

| | Three Months Ended June 30, | | Increase/(Decrease) | |
|--|--------------------------------|-------------|---------------------|----|
| | 2005 | 2004 | \$ | % |
| Contract research, service and license revenues | \$2,810,000 | \$2,749,000 | \$ 61,000 | 2% |

Edgar Filing: SPIRE CORP - Form 10QSB

| | | | | |
|------------------------|-------------|-------------|-------------|------|
| Sales of goods | 4,537,000 | 1,509,000 | 3,028,000 | 201% |
| | ----- | ----- | ----- | |
| Net sales and revenues | \$7,347,000 | \$4,258,000 | \$3,089,000 | 73% |
| | ===== | ===== | ===== | |

13

The 2% increase in contract research, service and license revenues for the three months ended June 30, 2005 as compared to the three months ended June 30, 2004 is primarily attributable to an increased demand for Spire's biomedical processing services and an increase in research and development activities both partially offset by a decrease in Bandwidth foundry services. Biomedical processing services revenues increased 5% due to increased demand for Spire's IONGUARD implant services. Revenues from research and development activities increased 1% in 2005 as compared to 2004 primarily due to an increase in the number of contracts associated with funded research and development activities partially offset by a decrease in revenue from activities associated with our cost sharing agreement with NREL.

The 201% increase in sales of goods for the three months ended June 30, 2005 as compared to the three months ended June 30, 2004 was primarily due to increases in solar equipment and solar systems revenues and, to a lesser extent, an increase in biomedical product sales. Solar equipment and solar system revenues increased 316% and 198%, respectively, as compared to 2004 primarily due to the timing and delivery of customer orders. The 2005 results include the sale of two photovoltaic module production lines in 2005 versus none in 2004 and the completion of a large solar system installation in Chicago. Biomedical product sales increased 78% in 2005 as compared to 2004 as a result of increased demand for Spire's line of hemodialysis catheters.

The following table categorizes the Company's net sales and revenues for the periods presented:

| | Six Months Ended June 30, | | Increase/(Decrease) | |
|--|------------------------------|-------------|---------------------|-------|
| | 2005 | 2004 | \$ | % |
| | ----- | ----- | ----- | ----- |
| Contract research, service and license revenues | \$ 5,542,000 | \$5,331,000 | \$ 211,000 | 4% |
| Sales of goods | 5,985,000 | 3,957,000 | 2,028,000 | 51% |
| | ----- | ----- | ----- | |
| Net sales and revenues | \$11,527,000 | \$9,288,000 | \$2,239,000 | 24% |
| | ===== | ===== | ===== | |

The 4% increase in contract research, service and license revenues for the six months ended June 30, 2005 as compared to the six months ended June 30, 2004 is primarily attributable to an increase in research and development activities partially offset by decreases in Bandwidth foundry services. Revenues from Spire's research and development activities increased 18% in 2005 as compared to 2004 primarily due to an increase in the number of contracts associated with funded research and development partially offset by a decrease in revenue from activities associated with our cost sharing agreement with NREL. Revenues from Bandwidth foundry services decreased 4% in 2005 compared to 2004 due to the timing and delivery of customer orders.

The 51% increase in sales of goods for the six months ended June 30, 2005 as compared to the six months ended June 30, 2004 was primarily due to increases in solar equipment revenues and biomedical product sales partially offset by a decrease in solar system revenue. Solar equipment revenues increased 108% in 2005 as compared to 2004 due to the timing and delivery of customer orders. The 2005 results include the sale of two photovoltaic module production lines in

Edgar Filing: SPIRE CORP - Form 10QSB

2005 versus none in 2004. Biomedical product sales increased 95% in 2005 as compared to 2004 as a result of increased demand for Spire's line of hemodialysis catheters. Solar systems revenues decreased 12% in 2005 as compared to 2004 primarily due to the timing and delivery of customer orders.

COST OF SALES AND REVENUES

The following table categorizes the Company's cost of sales and revenues for the periods presented, stated in dollars and as a percentage of related sales and revenues:

| | Three Months Ended June 30, | | | | Increase/ (Decrease) | |
|--|-----------------------------|-----|-------------|-----|-------------------------|------|
| | 2005 | % | 2004 | % | \$ | % |
| Cost of contract research, services and licenses | \$2,158,000 | 77% | \$2,113,000 | 77% | \$ 45,000 | 2% |
| Cost of goods sold | 4,292,000 | 94% | 1,388,000 | 92% | 2,904,000 | 209% |
| Net cost of sales and revenues | \$6,450,000 | 87% | \$3,501,000 | 82% | \$2,949,000 | 84% |

The \$45,000 (2%) increase in cost of contract research and service revenues in 2005 is primarily due to a 7% increase in the cost of the Company's research and development activities associated with its 1% increase in revenues. Cost of contract research, services and licenses as a percentage of revenue remained relatively unchanged as the cost increases discussed above were substantially offset by margin improvement within biomedical processing services.

14

The \$2,904,000 (209%) increase in cost of goods sold is primarily due to an 128% increase in Spire's solar equipment direct costs resulting from its 316% increase in revenues discussed above and increases in solar systems and biomedical products unit's direct costs resulting from its 198% and 78% increase in revenues, respectively. The increase in cost of goods sold as a percentage of revenue is the result of sales mix and lower than expected contribution margins in the solar systems revenues.

COST OF SALES AND REVENUES

| | Six Months Ended June 30, | | | | Inco |
|--|---------------------------|-----|--------------|-----|-------|
| | 2005 | % | 2004 | % | |
| Cost of contract research, services and licenses | \$ 4,275,000 | 77% | \$ 4,119,000 | 77% | \$ |
| Cost of goods sold | 5,711,000 | 95% | 3,309,000 | 84% | 2, |
| Net cost of sales and revenues | \$ 9,986,000 | 86% | \$ 7,428,000 | 80% | \$ 2, |

The \$156,000 (4%) increase in cost of contract research and service revenues in 2005 is primarily due to a 40% increase in the cost of the Company's research and development activities associated with its 18% increase in revenues. Cost of contract research, services and licenses as a percentage of revenue remained relatively unchanged as the cost increases discussed above were substantially offset by margin improvement within biomedical processing

Edgar Filing: SPIRE CORP - Form 10QSB

services.

The \$2,402,000 (73%) increase in cost of goods sold is primarily due to an increase in Spire's solar equipment direct costs resulting from its 108% increase in revenues discussed above, to a lesser extent, an increase in biomedical products unit's direct costs resulting from its 95% increase in revenues discussed above. The increase in cost of goods sold as a percentage of revenue is the result of lower than expected contribution margins in the solar equipment and solar systems segments. The effect of these lower than expected contribution margins was partially offset by an improved contribution margin in our biomedical product line.

OPERATING EXPENSES

The following table categorizes the Company's operating expenses for the periods presented, stated in dollars and as a percentage of related sales and revenues:

| | Three Months Ended June 30, | | | | Inc |
|-------------------------------------|-----------------------------|-----|--------------|-----|-----|
| | 2005 | % | 2004 | % | |
| Selling, general and administrative | \$ 2,057,000 | 28% | \$ 2,030,000 | 48% | \$ |
| Internal research and development | 341,000 | 5% | 377,000 | 9% | |
| Operating expenses | \$ 2,398,000 | 33% | \$ 2,407,000 | 57% | \$ |

INTERNAL RESEARCH AND DEVELOPMENT

The decrease in research and development costs was primarily a result of the Company's reduced effort in the "next generation" solar energy module manufacturing equipment under a cost-sharing contract with the Department of Energy National Renewable Energy Laboratory ("NREL"). The decrease in research and development expenses as a percentage of sales and revenues was primarily due to the increase in sales and revenue.

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES

Selling, general and administrative expenses for the three months ended June 30, 2005 increased by \$27,000. The increase was primarily due to increased legal and sales and marketing costs, which were partially offset by a reduction in insurance expense for the quarter. The decrease in selling, general and administrative expenses as a percentage of sales and revenues is primarily due to the increase in sales and revenue.

15

The following table categorizes the Company's operating expenses for the periods presented, stated in dollars and as a percentage of related sales and revenues:

| | Six Months Ended June 30, | | | | Inc |
|-------------------------------------|---------------------------|-----|--------------|-----|------|
| | 2005 | % | 2004 | % | |
| Selling, general and administrative | \$ 3,887,000 | 34% | \$ 4,089,000 | 44% | \$ (|
| Internal research and development | 658,000 | 6% | 731,000 | 8% | |
| | \$ | % | \$ | % | \$ (|

Edgar Filing: SPIRE CORP - Form 10QSB

| | | | | | |
|--------------------|--------------|-----|--------------|-----|-------|
| Operating expenses | \$ 4,545,000 | 39% | \$ 4,820,000 | 52% | \$ (|
| | ===== | | ===== | | ===== |

INTERNAL RESEARCH AND DEVELOPMENT

The decrease in research and development costs was primarily a result of the Company's reduced effort in the "next generation" solar energy module manufacturing equipment under a cost-sharing contract with the Department of Energy National Renewable Energy Laboratory ("NREL"). The decrease in research and development expenses as a percentage of sales and revenues was primarily due to the increase in sales and revenue partially offset by the decrease in research and development costs described above.

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES

The decrease was due primarily to decreased cost associated with legal and audit expenses in connection with compliance requirements and, to a lesser extent, decreased insurance costs. These decreases were partially offset by increased cost associated with sales and marketing efforts of the Company's biomedical product line and solar business units. The decrease in selling, general and administrative expenses as a percentage of sales and revenues was primarily due to the increase in sales and revenues and, to a lesser extent, the decrease in selling, general and administrative costs discussed above.

OTHER EXPENSE, NET

The Company earned \$9,000 and \$14,000 of interest income for the three months ended June 30, 2005 and 2004, respectively. The Company incurred interest expense of \$67,000 and \$84,000 for the three months ended June 30, 2005 and 2004, respectively. The interest expense is primarily associated with interest incurred on capital leases associated with the semiconductor foundry.

The Company earned \$18,000 and \$34,000 of interest income for the six months ended June 30, 2005 and 2004, respectively. The Company incurred interest expense of \$153,000 and \$174,000 for the six months ended June 30, 2005 and 2004, respectively. The interest expense is primarily associated with interest incurred on capital leases associated with the semiconductor foundry.

During the second quarter of 2005, the Company recorded \$63,000 of currency transaction loss related to the sale of a solar technology license.

INCOME TAXES

The Company did not record an income tax provision for the three and six months ended June 30, 2005 and 2004 as earnings (loss) before income is expected to be substantially offset by net operating loss carryforwards of approximately \$3.5 million. A valuation allowance was provided against the deferred tax assets generated in 2004.

NET EARNINGS (LOSS)

The Company reported net earnings for the three months ended June 30, 2005 of \$4,698,000, compared to net earnings of \$1,279,000 in 2004. The increase in net earnings in 2005 versus 2004 is primarily due to the gain on the sale of a license to our solar technology.

The Company reported net earnings for the six months ended June 30, 2005 of \$3,118,000, compared to a net loss of \$99,000 in 2004. The increase in net earnings in 2005 versus 2004 is primarily due to the gain on the sale of a license to our solar technology.

Edgar Filing: SPIRE CORP - Form 10QSB

16

Liquidity and Capital Resources

| | June 30, 2005 | December 31, 2004 | Increase/ (Decrease) | |
|---------------------------|------------------|----------------------|----------------------|------|
| | | | \$ | % |
| Cash and cash equivalents | \$7,576,000 | \$3,337,000 | \$4,239,000 | 127% |
| Working capital | 7,591,000 | 3,996,000 | 3,595,000 | 90% |

Cash and cash equivalents increased primarily due to the proceeds from sale of licenses partially offset by cash used in operations and, to a lesser extent, investments in patents and licenses and payments on capital leases.

The Company has historically funded its operating cash requirements using operating cash flow and proceeds from the sale and licensing of technology. The Company's liquidity position benefited as a result of a cash receipt of \$3,000,000 in 2005 and 2004 arising from the sale of a hemodialysis patent license to Bard Access Systems. The Company received its final payment of \$3,000,000 in June 2005. In addition, the Company received JPY 400,000,000 (approximately \$3.7 million) in June 2005 due to the sale of a license to our solar technology.

The Company has a \$2,000,000 Loan Agreement (the "Agreement") with Citizens Bank of Massachusetts (the "Bank"). The Agreement provides Standby Letter of Credit guarantees for certain foreign and domestic customers, which are 100% secured with cash. At June 30, 2005, the Company had \$1,189,000 of restricted cash associated with outstanding Letters of Credit. Standby Letters of Credit under this Agreement bear interest at 1%. The Agreement also provides the Company with the ability to convert to a \$2,000,000 revolving line of credit, based upon eligible accounts receivable and certain conversion covenants. Loans under this revolving line of credit bear interest at the Bank's prime rate as determined plus 1/2% (6.75% at June 30, 2005.) At June 30, 2005, the Company had not exercised its conversion option and no amounts were outstanding under the revolving line of credit. A commitment fee of .25% is charged on the unused portion of the borrowing base. On June 29, 2005, the Company entered into a Second Amendment to extend the expiration date of the Agreement to June 27, 2006. The Agreement contains covenants including certain financial reporting requirements. At June 30, 2005, the Company was in compliance with its financial reporting requirements and cash balance covenants.

To date, there are no material commitments by the Company for capital expenditures. At June 30, 2005, the Company's retained earnings were \$1,468,000, compared to an accumulated deficit of \$1,649,000 as of December 31, 2004. Working capital as of June 30, 2005 increased 90% to \$7,591,000, compared to \$3,996,000 as of December 31, 2004.

The Company believes it has sufficient resources to finance its current operations for the foreseeable future from operating cash flow and working capital.

Impact of Inflation and Changing Prices

Historically, the Company's business has not been materially impacted by inflation. Manufacturing equipment and solar systems are generally quoted, manufactured and shipped within a cycle of approximately nine months, allowing for orderly pricing adjustments to the cost of labor and purchased parts. The Company has not experienced any negative effects from the impact of inflation on long-term contracts. The Company's service business is not expected to be

Edgar Filing: SPIRE CORP - Form 10QSB

seriously affected by inflation because its procurement-production cycle typically ranges from two weeks to several months, and prices generally are not fixed for more than one year. Research and development contracts usually include cost escalation provisions.

Foreign Currency Fluctuation

The Company sells only in U.S. dollars, generally against an irrevocable confirmed letter of credit through a major United States bank. Therefore the Company is not directly affected by foreign exchange fluctuations on its current orders. However, fluctuations in foreign exchange rates do have an effect on the Company's customers' access to U.S. dollars and on the pricing competition on certain pieces of equipment that the Company sells in selected markets. The Company received Japanese yen in exchange for the sale of a license to its solar technology. In addition, purchases made and royalties received under the Company's consortium agreement with its Japanese partner will be in Japanese yen. The Company does not believe that foreign exchange fluctuations will materially affect its operations.

17

Related Party Transactions

The Company subleases 74,000 square-feet in a building leased by Mykrolis Corporation, who in turn leases the building from a Trust of which Roger G. Little, Chairman of the Board, Chief Executive Officer and President of the Company, is sole trustee and principal beneficiary. The Company believes that the terms of the third-party sublease are commercially reasonable. The 1985 sublease originally was for a period of ten years, was extended for a five-year period expiring on November 30, 2000 and was further extended for a five-year period expiring on November 30, 2005. The agreement provides for minimum rental payments plus annual increases linked to the consumer price index. Rent expense under this sublease for the quarter ended June 30, 2005 was \$571,000. In connection with this sublease, the Company is invoiced and pays certain trust related expenses, including building maintenance and insurance. The Company invoices the Trust on a monthly basis and the Trust reimburses the Company for all such costs. No amounts were due from the Trust as of June 30, 2005.

In conjunction with the acquisition of Bandwidth by the Company, the Company released Bandwidth from the lease agreement that had existed between Bandwidth and the Company. In November 2001, Bandwidth, under its previous owner, abandoned the space being subleased from the Company in Bedford, Massachusetts, to move to a new building and wafer fabrication lab in Hudson, New Hampshire. At that time, there were 48 months left on the lease. Subsequent to the move to Hudson, New Hampshire, Bandwidth was unable to sublease the Bedford, Massachusetts space, and was paying the Company for the unused space. In conjunction with the acquisition of Bandwidth in May 2003, the Company released Bandwidth from the remaining lease payments. However, the Company continues to be obligated to Mykrolis Corporation for the entire amount of the remaining lease agreement. As a result, the present value of the remaining lease obligation associated with the unused space was recorded as an assumed liability of \$1,247,241 in the purchase accounting. As of June 30, 2005, the remaining lease obligation is \$217,411, which is reflected as "accrued lease obligation - related party" in the June 30, 2005 unaudited condensed consolidated balance sheet. The difference between the actual rent payment and the discounted rent payment will be accreted to the consolidated statements of operations as interest expense. Interest of 4.75% has been assumed on this obligation. For the six months ended June 30, 2005, interest expense was approximately \$9,000.

Also in conjunction with the acquisition of Bandwidth by the Company,

Edgar Filing: SPIRE CORP - Form 10QSB

SPI-Trust, a Trust of which Roger G. Little, Chairman of the Board, Chief Executive Officer and President of the Company, is sole trustee and principal beneficiary, purchased from Stratos (Bandwidth's former owner) the building that Bandwidth occupies in Hudson, New Hampshire for \$3.7 million. Subsequently, the Company entered into a lease for the building (90,000 square feet) with SPI-Trust whereby the Company will pay \$4.1 million to the SPI-Trust over an initial five-year term expiring in 2008 with a Company option to extend for five years. In addition to the rent payments, the lease obligates the Company to keep on deposit with SPI-Trust the equivalent of three months rent (\$191,250 as of June 30, 2005.) The lease agreement does not provide for a transfer of ownership at any point. Interest costs were assumed at 7%. For the six months ended June 30, 2005, interest expense was approximately \$94,000. This lease has been classified as a related party capital lease and a summary of payments (including interest) follows:

| YEAR | RATE PER SQUARE FOOT | ANNUAL RENT | MONTHLY RENT | SECURITY DEPOSIT |
|-----------------------------|-------------------------|--------------|--------------|------------------|
| ----- | ----- | ----- | ----- | ----- |
| June 1, 2003 - May 31, 2004 | \$ 6.00 | \$ 540,000 | \$ 45,000 | \$135,000 |
| June 1, 2004 - May 31, 2005 | 7.50 | 675,000 | 56,250 | 168,750 |
| June 1, 2005 - May 31, 2006 | 8.50 | 765,000 | 63,750 | 191,250 |
| June 1, 2006 - May 31, 2007 | 10.50 | 945,000 | 78,750 | 236,250 |
| June 1, 2007 - May 31, 2008 | 13.50 | 1,215,000 | 101,250 | 303,750 |
| | | ----- | | |
| | | \$ 4,140,000 | | |
| | | ===== | | |

At June 30, 2005, \$621,000 and \$1,925,000 are reflected as the current and long-term portions of capital lease obligation - related party, respectively, on the unaudited condensed consolidated balance sheet.

Critical Accounting Policies

The preparation of financial statements in accordance with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Among the significant estimates affecting our consolidated financial statements are those relating to revenue recognition, reserves for doubtful accounts and sales returns and allowances, reserve for excess and

18

obsolete inventory, impairment of long-lived assets, acquisition accounting, income taxes, and warranty reserves. We regularly evaluate our estimates and assumptions based upon historical experience and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. To the extent actual results differ from those estimates, our future results of operations may be affected. We believe the following critical accounting policies affect our more significant judgments and estimates used in the preparation of our consolidated financial statements. Refer to Footnote 2 of our notes to consolidated financial statements in our annual report on Form 10-KSB for the year ended December 31, 2004 for a description of our accounting policies for income taxes and warranties.

REVENUE RECOGNITION

Edgar Filing: SPIRE CORP - Form 10QSB

The Company derives its revenues from three primary sources: (1) commercial products including, but not limited to, solar energy manufacturing equipment, solar energy systems and hemodialysis catheters; (2) biomedical and semiconductor processing services; and (3) United States government funded research and development contracts.

We generally recognize product revenue upon shipment of products provided there are no uncertainties regarding customer acceptance, persuasive evidence of an arrangement exists, the sales price is fixed or determinable, and collectibility is reasonably assured. These criteria are generally met at the time of shipment when the risk of loss and title passes to the customer or distributor, unless a consignment arrangement exists. Revenue from consignment arrangements is recognized based on product usage indicating sales are complete. Gross sales reflect reductions attributable to customer returns and various customer incentive programs including pricing discounts and rebates. Product returns are permitted in certain sales contracts and an allowance is recorded for returns based on the Company's history of actual returns. Certain customer incentive programs require management to estimate the cost of those programs. The allowance for these programs is determined through an analysis of programs offered, historical trends, expectations regarding customer and consumer participation, sales and payment trends, and experience with payment patterns associated with similar programs that had been previously offered. If sufficient history to make reasonable and reliable estimates of returns or rebates does not exist, revenue associated with such practices is deferred until the return period lapses or a reasonable estimate can be made. This deferred revenue will be recognized as revenue when the distributor reports to us that it has either shipped or disposed of the units (indicating that the possibility of return is remote).

The Company's OEM capital equipment solar energy business builds complex customized machines to order for specific customers. Substantially all of these orders are sold on a FOB Bedford, Massachusetts (or EXW Factory) basis. It is the Company's policy to recognize revenues for this equipment as the product is shipped to the customer, as customer acceptance is obtained prior to shipment and the equipment is expected to operate the same in the customer's environment as it does in the Company's environment. When an arrangement with the customer includes future obligations or customer acceptance, revenue is recognized when those obligations are met or customer acceptance has been achieved. The Company's solar energy systems business installs solar energy systems on customer-owned properties on a contractual basis. Generally, revenue is recognized once the systems have been installed and the title is passed to the customer. For arrangements with multiple elements, the Company allocates fair value to each element in the contract and revenue is recognized upon delivery of each element. If the Company is not able to establish fair value of undelivered elements, all revenue is deferred.

The Company recognizes revenues and estimated profits on long-term government contracts on the accrual basis where the circumstances are such that total profit can be estimated with reasonable accuracy and ultimate realization is reasonably assured. Profit estimates are revised periodically based upon changes and facts, and any losses on contracts are recognized immediately. Some of the contracts include provisions to withhold a portion of the contract value as retainage until such time as the United States government performs an audit of the cost incurred under the contract. The Company's policy is to take into revenue the full value of the contract, including any retainage, as it performs against the contract since the Company has not experienced any substantial losses as a result of audits performed by the United States government.

IMPAIRMENT OF LONG-LIVED ASSETS

Long-lived assets, including fixed assets and intangible assets, are

Edgar Filing: SPIRE CORP - Form 10QSB

continually monitored and are evaluated at least annually for impairment. The determination of recoverability is based on an estimate of undiscounted cash flows expected to result from the use of an asset and its eventual disposition. The estimate of cash flows is based upon, among other things, certain assumptions about expected future operating performance. Our estimates of undiscounted cash flows may differ from actual cash flows due to, among other things, technological changes, economic conditions, changes to our business model or changes in our operating performance. If the sum of the undiscounted cash flows (excluding interest) is less than

19

the carrying value, we recognize an impairment loss, measured as the amount by which the carrying value exceeds the fair value of the asset.

ACQUISITION ACCOUNTING

Through its acquisition, the Company has accumulated assets the valuation of which involves estimates based on fair value assumptions. Estimated lives assigned to the assets acquired in a business purchase also involve the use of estimates. These matters that are subject to judgments and estimates are inherently uncertain, and different amounts could be reported using different methodologies. Management uses its best estimate in determining the appropriate values and estimated lives to reflect in the consolidated financial statements, using historical experience, market data, and all other available information.

Contractual Obligations, Commercial Commitments and Off-Balance Sheet

Arrangements

The following table summarizes the Company's gross contractual obligations at June 30, 2005 and the maturity periods and the effect that such obligations are expected to have on its liquidity and cash flows in future periods:

| CONTRACTUAL OBLIGATIONS | PAYMENTS DUE BY PERIOD | | | | |
|----------------------------------|------------------------|---------------------|----------------|----------------|---------------------|
| | TOTAL | LESS THAN 1 YEAR | 2 - 3 YEARS | 4 - 5 YEARS | MORE THAN 5 YEAR |
| PURCHASE OBLIGATIONS | \$3,144,000 | \$2,617,000 | \$ 527,000 | \$ | -- |
| CAPITAL LEASES: | | | | | |
| Unrelated party capital lease | \$ 714,000 | \$ 437,000 | \$ 277,000 | \$ | -- |
| Related party capital lease | 2,850,000 | 780,000 | 2,070,000 | | -- |
| OPERATING LEASES: | | | | | |
| Unrelated party operating leases | \$ 193,000 | \$ 63,000 | \$ 108,000 | \$ | 22,000 |
| Related party operating lease | 507,000 | 507,000 | | | -- |
| | | | | | -- |

Purchase obligations include all open purchase orders outstanding regardless of whether they are cancelable or not.

Capital lease obligations outlined above include both the principal and interest components of these contractual obligations. Included in the related party operating lease is the accrued lease obligation in the amount of \$217,000.

On October 8, 1999, the Company entered into an Agreement with BP Solarex ("BPS") in which BPS agreed to purchase certain production equipment built by

Edgar Filing: SPIRE CORP - Form 10QSB

the Company, for use in the Company's Chicago factory ("Spire Solar Chicago") and in return the Company agreed to purchase solar cells of a minimum of two megawatts per year over a five-year term for a fixed fee from BPS (the "Purchase Commitment"). BPS has the right to reclaim the equipment should the Company not meet its obligations in the Purchase Commitment. The proceeds from the sale of the production equipment purchased by BPS have been classified as an unearned purchase discount in the accompanying unaudited condensed consolidated balance sheet. The Company will amortize this discount as a reduction to cost of sales as it purchases solar cells from BPS. During the quarter ended September 30, 2003, the Company and BPS retroactively amended the agreement to include all purchases of solar modules, solar systems, inverter systems and other system equipment purchased by the Company from BPS in the purchase commitment calculation. Amortization of the purchase discount amounted to \$54,128 for the six-months ended June 30, 2005. The production equipment has been classified as a component of fixed assets in the accompanying unaudited condensed consolidated balance sheet. Depreciation amounted to \$136,256 for the six months ended June 30, 2005.

In addition, the agreement contains a put option for BPS to have the Company create a separate legal entity for Spire Solar Chicago and for BPS to convert the value of the equipment and additional costs, as defined, into equity of the new legal entity. The percentage ownership in the joint venture would be determined based on the cumulative investments by BPS and the Company.

The amended agreement also allows the Company to terminate the agreement on 30 days notice in consideration for a termination payment based on the aggregate amount of Spire purchases of BPS products and the fair market value of the production equipment purchased by BPS at the time of the termination election. The Company is currently exploring

20

various options with regard to this agreement including a potential purchase of the production equipment. As of June 30, 2005 a definitive decision has not been made.

In October 2002, the Company sold an exclusive patent license for a hemodialysis split-tip catheter to Bard Access Systems, Inc. ("Bard"), a wholly owned subsidiary of C. R. Bard, Inc., in exchange for \$5,000,000 upon the execution of the agreement, with another \$5,000,000 due upon the earlier to occur of: (a) the date of the first commercial sale of a licensed product by Bard; or (b) no more than 18 months after signing. The agreement further provided for two additional contingent cash payments of \$3,000,000 each upon the completion of certain milestones by Bard in 2004 and 2005. Bard has the right to cancel the agreement at any time subsequent to the second payment. During the year ended December 31, 2002, the Company recorded the initial payment under the agreement, resulting in a gain of \$4,464,929, net of direct costs. Due to the potential length of time between the first and second payments and the cancellation provisions within the agreement, the Company did not record the potential remaining payments at that time. During June 2003, in accordance with the agreement, the Company received notification from Bard of the first commercial sale, collected the \$5,000,000 payment due and recorded a gain of \$4,989,150, net of direct costs. In June 2004, the Company received the first contingent milestone payment and recorded a gain of \$3,000,000. In June 2005, the Company received the second and final contingent milestone payment and recorded a gain of \$3,000,000. There were no direct costs associated with these payments. These gains have been recorded in the accompanying unaudited condensed consolidated statements of operations for three and six months ended June 30, 2005 and 2004, respectively.

In conjunction with the sale, the Company received a sublicense, which permits the Company to continue to manufacture and market hemodialysis catheters

Edgar Filing: SPIRE CORP - Form 10QSB

for the treatment of chronic kidney disease. In addition, the Company granted Bard a right of first refusal should the Company seek to sell the catheter business.

On May 26, 2005, the Company entered into a global consortium agreement (the "Agreement") with Nisshinbo Industries, Inc. (Nisshinbo) for the development, manufacturing, and sales of solar photovoltaic module manufacturing equipment. Under the terms of the Agreement, Nisshinbo purchased a license to manufacture and sell the Company's module manufacturing equipment for an upfront fee plus additional royalties based on ongoing equipment sales over a ten-year period. In addition, the Company and Nisshinbo agreed, but are not obligated, to pursue joint research and development, product improvement activities and sales and marketing efforts. On June 27, 2005, the Company received JPY 400,000,000 from the sale of this permanent license. The Company has determined the fair value of the license and royalty based on an appraisal. As a result, a \$3,319,600 gain has been recognized as a gain on sale of license in the accompanying unaudited condensed consolidated statements of operations for the three and six months ended June 30, 2005. In addition, approximately \$13,000 of royalty income was recognized during the quarter.

As of June 30, 2005, JPY 400,000,000 was held in a Japanese yen account. This yen account has been reflected in cash and cash equivalents in the accompanying unaudited condensed consolidated balance sheet utilizing the closing yen/dollar exchange rate as of June 30, 2005. As a result, a \$62,845 currency transaction loss was incurred and reflected in Other expense, net in the accompanying unaudited condensed consolidated statement of operations for the three and six months ended June 30, 2005. On July 1, the Company entered into a 30-day Forward Plus Contract with its Bank for the conversion of the majority of its Yen account into United States dollars at a predetermined exchange rate range. This contract effectively capped the Company's exchange rate at 113.25 while allowing the Company to benefit from decreases in the yen / dollar exchange rate to a 109.25 limit. If the rate dropped below this limit at the expiration date of the contract, the Company would have to convert the yen at the 113.25 rate. On August 3, 2005, the Company converted JPY 350,000,000 into \$3,139,295 and the contract expired.

The Company believes that the sale of these licenses does not reflect the day-to-day operations of the Company. Therefore, the net proceeds received have been classified under investing activities in the unaudited condensed consolidated statements of cash flows for the six months ended June 30, 2005 and June 30, 2004, respectively.

Outstanding letters of credit totaled \$1,189,000 at June 30, 2005. The letters of credit principally secure performance obligations, and allow holders to draw funds up to the face amount of the letter of credit if the Company does not perform as contractually required. These letters of credit expire through 2007 and are 100% secured by cash.

21

ITEM 3. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

As required by Rule 13a-15 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), the Company carried out an evaluation under the supervision and with the participation of the Company's management, including the Chief Executive Officer and President and the Chief Financial Officer, of the effectiveness of the Company's disclosure controls and procedures as of March 31, 2005. In designing and evaluating the Company's disclosure controls

Edgar Filing: SPIRE CORP - Form 10QSB

and procedures, the Company and its management recognize that there are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their desired control objectives. Additionally, in evaluating and implementing possible controls and procedures, the Company's management was required to apply its reasonable judgment. Furthermore, in the course of this evaluation, management considered certain internal control areas, including those discussed below, in which we have made and are continuing to make changes to improve and enhance controls. Based upon the required evaluation, the Chief Executive Officer and the Chief Financial Officer concluded that as of June 30, 2005 the Company's disclosure controls and procedures were effective (at the "reasonable assurance" level mentioned above) to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms.

From time to time, the Company and its management have conducted and will continue to conduct further reviews and, from time to time put in place additional documentation, of the Company's disclosure controls and procedures, as well as its internal control over financial reporting. The Company may from time to time make changes aimed at enhancing their effectiveness, as well as changes aimed at ensuring that the Company's systems evolve with, and meet the needs of, the Company's business. These changes may include changes necessary or desirable to address recommendations of the Company's management, its counsel and/or its independent auditors, including any recommendations of its independent auditors arising out of their audits and reviews of the Company's financial statements. These changes may include changes to the Company's own systems, as well as to the systems of businesses that the Company has acquired or that the Company may acquire in the future and will, if made, be intended to enhance the effectiveness of the Company's controls and procedures. The Company is also continually striving to improve its management and operational efficiency and the Company expects that its efforts in that regard will from time to time directly or indirectly affect the Company's disclosure controls and procedures, as well as the Company's internal control over financial reporting.

As disclosed in our quarterly report on Form 10-QSB/A Amendment Number 2 for the quarterly period ended June 30, 2003, as amended (the "Second Quarter Form 10-QSB"), in connection with the initial filing of the Second Quarter Form 10-QSB, which was initially submitted prior to the completion of the required SAS 100 Review by the Company's independent auditors, the Audit Committee engaged outside counsel to conduct an investigation into the events surrounding the preparation and filing of the Second Quarter Form 10-QSB. Based on the results of that investigation, outside counsel concluded that weaknesses existed in the Company's disclosure controls and procedures and proposed an action plan designed to strengthen the Company's disclosure controls and procedures. The Audit Committee, the Board of Directors and management have begun to adopt and implement certain of those recommendations in order to strengthen the Company's disclosure controls and procedures.

As disclosed in our annual report on Form 10-KSB for the year ended December 31, 2003, the Company's independent auditor, Vitale, Caturano & Company, Ltd. ("VCC") advised management and the Audit Committee by a letter dated March 18, 2004 that, in connection with its audit of the Company's consolidated financial statements for the year ended December 31, 2003, it noted certain matters involving internal control and its operation that it considered to be a material weakness under standards established by the American Institute of Certified Public Accountants. Reportable conditions are matters coming to an independent auditors' attention that, in their judgment, relate to significant deficiencies in the design or operation of internal control and could adversely affect the organization's ability to record, process, summarize, and report

Edgar Filing: SPIRE CORP - Form 10QSB

financial data consistent with the assertions of management in the financial statements. Further, a material weakness is a reportable condition in which the design or operation of one or more internal control components does not reduce to a relatively low level the risk that errors or fraud in amounts that would be material in relation to the financial statements being audited may occur and not be detected within a timely period by employees in the normal course of performing their assigned functions. VCC advised management and the Audit Committee that it considered the following to constitute material weaknesses in internal control and operations: (i) the Company's failure to adequately staff its finance group with the appropriate level of experience to effectively control the increased level of transaction activity, address the complex accounting matters and manage the increased financial reporting complexities resulting from, among other things,

22

the acquisition of Bandwidth, the implementation of a new financial reporting system and the investigation surrounding the filing and eventual restatement of the Company's Form 10-QSB, as amended, for the quarter ended June 30, 2003 and (ii) the Company's current monthly close process does not mitigate the risk that material errors could occur in the books, records and financial statements, and does not ensure that those errors would be detected in a timely manner by the Company's employees in the normal course of performing their assigned functions. The matter noted in clause (i) above was similar to the material weakness noted by our former independent auditor (as disclosed in prior SEC filings). VCC noted that these matters were considered by it during its audit and did not modify the opinion expressed in its independent auditor's report dated March 18, 2004.

On March 24, 2005, VCC issued a letter advising management and the Audit Committee, that, in connection with its audit of the Company's consolidated financial statements for the year ended December 31, 2004, it continued to note certain matters involving internal control and its operation previously outlined in their March 18, 2004 letter that it considered to be a material weakness under standards established by the American Institute of Certified Public Accountants. VCC noted that the Company had implemented several of the specific recommendations in their March 18, 2004 letter including, but not exclusive of:

- o An improved reconciliation process;
- o A disciplined and timely close process on a monthly basis; and
- o Detailed reviews of monthly close packages by the appropriate levels of management.

However, VCC also noted that improvements still need to be made in the reconciliation and documentation and information flow processes. In addition, VCC noted that while an internal assessment of the finance staff has been made and certain roles and responsibilities have been defined, the appropriate level of staffing within the finance department will not be alleviated until such time as the full finance team is assembled.

The Company concurs with VCC's finding noted above and is continuing to make changes in its internal controls and procedures. The Company is also continually striving to improve its management and operational efficiency and expects that its efforts in that regard will from time to time directly or indirectly affect the Company's controls and procedures, including its internal control over financial reporting. The Company has reorganized the accounting staff and expects to hire additional professionals in the near term. In addition, the Company has completed compliance training and will continue to arrange for additional training for its finance staff.

Changes in Internal Control Over Financial Reporting

Edgar Filing: SPIRE CORP - Form 10QSB

There was no change in the Company's internal control over financial reporting that occurred during the first and second fiscal quarters of 2005 that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

PART II OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

From time to time, the Company is subject to legal proceedings and claims arising from the conduct of its business operations. The Company does not expect the outcome of these proceedings, either individually or in the aggregate, to have a material adverse effect on its financial position, results of operations, or cash flows.

The Company has been named as a defendant in 58 cases filed from August 2001 to July 2003 in state courts in Texas by persons claiming damages from the use of allegedly defective mechanical heart valves coated by a process licensed by the Company to St. Jude Medical, Inc., the valve manufacturer, which has also been named as a defendant in the cases. In June 2003, a judge in a state court in Harris County, Texas agreed to grant the Company's motion for summary judgment based upon the principle of federal preemption with regard to 57 of those cases and to order that the cases against the Company be dismissed with prejudice. An order to this effect was signed in late July 2003. The remaining case is still pending, and due to aspects of its fact situation is not subject to the principle of federal preemption. From August 2003 to date, a total of seven new cases were filed against the Company in courts in Harris County. Activity with regard to these cases is likely to occur only after the disposition of the original 57 cases is finally settled. The plaintiffs whose cases were dismissed have filed appeals with the Texas appellate court. In June 2005, the Texas Court of Appeals upheld the summary judgment granted by the lower court. Attorneys for the Company anticipate that the plaintiffs may file a motion for

23

rehearing, and an appeal with the Texas Supreme Court is also possible. Attorneys who represent the Company with respect to these cases in Texas do not believe at this time that the actions of a federal district court judge in Minnesota in denying St. Jude Medical's request for summary judgment will materially affect the Company's position in the Texas complaints.

During the second quarter of 2005 a suit was filed by Arrow International, Inc. against Spire Biomedical, Inc., a wholly owned subsidiary of the Company, alleging patent infringement by the Company. The complaint claims one of the Company's catheter products induces and contributes to infringement when medical professionals insert it. The Company has responded to the complaint denying all allegations and has filed certain counterclaims. The Company intends to vigorously defend this matter. In the opinion of management, an unfavorable outcome of this matter could have a material adverse effect on the Company's financial position as well as its results of operations and cash flows.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

Edgar Filing: SPIRE CORP - Form 10QSB

None.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

On May 17, 2005, the Company held a Special Meeting in Lieu of Annual Meeting of Stockholders.

The number of directors was fixed at eight, leaving one vacancy, Udo Henseler, David R. Lipinski, Mark C. Little, Roger G. Little, Michael J. Magliochetti, Guy L. Mayer and Roger W. Redmond were elected to the Board of Directors to hold office until the 2006 annual meeting of the stockholders. The results for Proposal Number 1 were as follows:

| NOMINEE ----- | SHARES VOTING FOR ----- | SHARES VOTING AGAINST OR AUTHORITY WITHHELD ----- | SHARES ABSTAINING ----- | BROKER NON-VOTES ----- |
|-------------------------|-------------------------------|---|-------------------------------|------------------------------|
| Udo Henseler | 6,060,970 | 77,165 | -- | -- |
| David R. Lipinski | 5,708,462 | 429,673 | -- | -- |
| Mark C. Little | 5,726,562 | 411,573 | -- | -- |
| Roger G. Little | 5,725,762 | 412,373 | -- | -- |
| Michael J. Magliochetti | 6,078,070 | 60,065 | -- | -- |
| Guy L. Mayer | 6,078,470 | 59,665 | -- | -- |
| Roger W. Redmond | 6,078,270 | 59,865 | -- | -- |

ITEM 5. OTHER INFORMATION

- a. None
- b. None

ITEM 6. EXHIBITS

- 10(n) Development, Manufacturing, and Sales Consortium Agreement between Nisshinbo Industries, Inc. and Spire Corporation, with an effective date of 16 May 2005.*
- 31.1 Certification of the Chairman of the Board, Chief Executive Officer and President pursuant to ss.302 of the Sarbanes-Oxley Act of 2002.
- 31.2 Certification of the Chief Financial Officer pursuant to ss.302 of the Sarbanes-Oxley Act of 2002.
- 32.1 Certification of the Chairman of the Board, Chief Executive Officer and President pursuant to 18 U.S.C. ss.1350, as adopted pursuant to ss.906 of the Sarbanes-Oxley Act of 2002.
- 32.2 Certification of the Chief Financial Officer pursuant to 18 U.S.C. ss.1350, as adopted pursuant to ss.906 of the Sarbanes-Oxley Act of 2002.

* Portions of this Exhibit have been omitted pursuant to a request for confidential treatment.

Edgar Filing: SPIRE CORP - Form 10QSB

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Spire Corporation

Dated: August 15, 2005

By: /s/ Roger G. Little

Roger G. Little
Chairman of the Board,
Chief Executive Officer
and President

Dated: August 15, 2005

By: /s/ James F. Parslow

James F. Parslow
Chief Financial Officer

25

EXHIBIT INDEX

| Exhibit | Description |
|---------|--|
| ----- | ----- |
| 10(n) | Development, Manufacturing, and Sales Consortium Agreement between Nisshinbo Industries, Inc. and Spire Corporation, with an effective date of 16 May 2005.* |
| 31.1 | Certification of the Chairman of the Board, Chief Executive Officer and President pursuant to ss.302 of the Sarbanes-Oxley Act of 2002 |

Edgar Filing: SPIRE CORP - Form 10QSB

- 31.2 Certification of the Chief Financial Officer pursuant to ss.302 of the Sarbanes-Oxley Act of 2002
- 32.1 Certification of the Chairman of the Board, Chief Executive Officer and President pursuant to 18 U.S.C. ss.1350, as adopted pursuant to ss.906 of the Sarbanes-Oxley Act of 2002
- 32.2 Certification of the Chief Financial Officer pursuant to 18 U.S.C. ss.1350, as adopted pursuant to ss.906 of the Sarbanes-Oxley Act of 2002

* Portions of this Exhibit have been omitted pursuant to a request for confidential treatment.